Flowable Hemostats Market Report 2025

This flowable hemostats market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The flowable hemostats market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to growth in elective surgeries, rising adoption of personalized medicine, increased healthcare spending, and expansion of healthcare infrastructure in emerging markets.

The flowable hemostats market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the increasing number of surgical procedures, rising prevalence of chronic diseases, growing demand for minimally invasive surgeries, and an expanding geriatric population requiring surgical care. Major trends in the forecast period include integration of advanced bioengineered materials, development of smart hemostatic products, robotic-assisted and minimally invasive surgical techniques, adoption of patient-specific and personalized hemostatic solutions, and advanced customization of hemostats.

The growth of the flowable hemostats market is expected to be driven by the rising number of surgical procedures. This increase is attributed to an aging population, which creates a higher demand for age-related surgeries, as well as technological advancements that have made surgeries safer and more accessible. Flowable hemostats are particularly valuable in surgical procedures for controlling bleeding in hard-to-reach areas or where traditional methods might be ineffective. For example, in June 2024, a report by the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional non-governmental organization, revealed that the total number of surgical and non-surgical procedures increased by 3.4% in 2023, reaching 34.9 million compared to the previous year. Thus, the growing number of surgical procedures is contributing to the expansion of the flowable hemostats market.

Major companies in the flowable hemostats market are concentrating on developing advanced hemostatic agents, such as no-swell technology, to meet the evolving needs of surgical procedures. No-swell technology describes a hemostatic agent that does not absorb fluids and expand, making it suitable for surgeries where swelling could lead to complications. For example, in January 2023, Medcura Inc., a US-based surgical technology company, received FDA breakthrough device designation for its LifeGel flowable technology. LifeGel is designed to control bleeding during surgeries where swelling is not acceptable. It is the first and only flowable hemostatic gel specifically addressing issues related to hemostatic swelling. The absorbable agent remains hydrated and ready-to-use without swelling, potentially reducing risks such as nerve injury and paralysis. It is cost-effective, retains antimicrobial properties, is relatively transparent, and adheres to tissues, offering a safer and more effective solution for managing bleeding in complex surgical procedures.

In May 2022, Ethicon, a company based in the United States that specializes in surgical technologies, purchased GATT Technologies B.V. for an undisclosed sum. The goal of this acquisition was to strengthen Ethicon's portfolio of hemostatic and sealant solutions by incorporating GATT Technologies' advanced products to enhance surgical results. GATT Technologies B.V., located in the Netherlands, is recognized for its innovative advancements in hemostatic and sealant products used in medical applications.

Major companies operating in the flowable hemostats market are Pfizer Inc., Johnson & Johnson Services Inc., Medtronic plc, Medline Industries Inc., Stryker Corporation, Baxter International Inc., B Braun Melsungen AG, Becton Dickinson and Company, Cook Medical Inc., Teleflex Incorporated, Mallinckrodt Pharmaceuticals, Integra LifeSciences Holdings Corporation, Gelita Medical GmbH, Ferrosan Medical Devices A/S, Marine Polymer Technologies Inc, Axio Biosolutions Private Limited, Hemostasis LLC, Aegis Lifesciences Private Limited, Medcura Health Inc, Arch Therapeutics Inc., Starch Medical Inc.

North America was the largest region in the flowable hemostats market in 2024. The regions covered in the flowable hemostats market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the flowable hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Flowable hemostats are gelatinous medical devices designed to control bleeding during surgery by adapting to irregular wound shapes for effective application. They aid clotting by creating a physical barrier and activating the body’s coagulation cascade, making them suitable for use in complex or delicate surgical areas.

The main types of flowable hemostats are active hemostats, passive hemostats, and combination hemostats. Active hemostats are specialized medical agents that actively contribute to the blood clotting process, enhancing hemostasis during surgeries or in bleeding situations. They can be made from materials such as porcine gelatin and bovine gelatin and are used in various surgical fields, including general, cardiac, vascular, neuro and spine, and orthopedic surgeries. These hemostats are designed to meet the needs of different end users, including hospitals, clinics, and ambulatory surgery centers.

The flowable hemostats market research report is one of a series of new reports that provides flowable hemostats market statistics, including flowable hemostats industry global market size, regional shares, competitors with a flowable hemostats market share, detailed flowable hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the flowable hemostats industry. This flowable hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The flowable hemostats market consists of sales of synthetic flowable hemostats, fibrin sealant-based hemostats, and collagen-based flowable hemostats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.